Skip to main content

Generation Bio to Present at 39th Annual J.P. Morgan Healthcare Conference

Written by Customer Service on . Posted in Public Companies.

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that the company will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021.
President and Chief Executive Officer Geoff McDonough, M.D., will provide an overview of the company’s progress and anticipated milestones for 2021.Generation Bio this week announced a scientific milestone with the first demonstration of a non-viral gene therapy platform enabling human factor VIII expression in mice with hemophilia A. Mean levels of factor VIII reached 23% of normal levels.The company also announced data confirming successful translation of the company’s liver-targeted lipid nanoparticle delivery system into non-human primates. Together, the data support the advancement of Generation Bio’s lead program in hemophilia A into IND-enabling studies.Presentation Details
Date: Tuesday, Jan. 12, 2021
Time: 2:50-3:30 p.m. ETA live webcast of the company presentation and Q&A session will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.About Generation BioGeneration Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is designed to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company’s efficient, scalable manufacturing process supports Generation Bio’s mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.For more information, please visit www.generationbio.com. Contact:Investors 
Maren Killackey
Generation Bio
mkillackey@generationbio.com
541-646-2420Media 
Alicia Webb
Generation Bio
awebb@generationbio.com
847-254-4275Stephanie Simon 
Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.